Eli Lilly & Co. (LLY)
Analysis of Liquidity Ratios
Low level of difficulty
Liquidity ratios measure the company’s ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Eli Lilly & Co., liquidity ratios
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Current ratio | 1.73 | 1.32 | 1.37 | 1.53 | 1.09 | |
| Quick ratio | 1.20 | 0.91 | 0.98 | 1.04 | 0.77 | |
| Cash ratio | 0.68 | 0.55 | 0.55 | 0.54 | 0.43 |
Based on: 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19).
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Eli Lilly & Co.’s current ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Eli Lilly & Co.’s quick ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Eli Lilly & Co.’s cash ratio improved from 2016 to 2017 and from 2017 to 2018. |
Current Ratio
Eli Lilly & Co., current ratio calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Current assets | 20,549,600 | 19,202,100 | 15,101,400 | 12,573,600 | 12,179,800 | |
| Current liabilities | 11,888,100 | 14,535,900 | 10,986,600 | 8,229,600 | 11,207,500 | |
| Liquidity Ratio | ||||||
| Current ratio1 | 1.73 | 1.32 | 1.37 | 1.53 | 1.09 | |
| Benchmarks | ||||||
| Current Ratio, Competitors2 | ||||||
| Abbott Laboratories | 1.62 | 2.26 | 4.02 | 1.54 | 1.45 | |
| AbbVie Inc. | 0.98 | 1.28 | 1.65 | 1.50 | 1.41 | |
| Allergan PLC | 1.13 | 1.16 | 2.27 | 1.03 | 1.37 | |
| Amgen Inc. | 2.79 | 5.49 | 4.11 | 4.44 | 4.95 | |
| Biogen Inc. | 2.32 | 2.34 | 2.55 | 2.60 | 2.11 | |
| Bristol-Myers Squibb Co. | 1.61 | 1.55 | 1.55 | 1.30 | 1.73 | |
| Celgene Corp. | 2.23 | 4.99 | 3.67 | 4.77 | 4.60 | |
| Gilead Sciences Inc. | 3.38 | 2.74 | 2.22 | 2.50 | 3.07 | |
| Johnson & Johnson | 1.47 | 1.41 | 2.47 | 2.17 | 2.36 | |
| Merck & Co. Inc. | 1.17 | 1.33 | 1.78 | 1.55 | 1.77 | |
| Pfizer Inc. | 1.57 | 1.35 | 1.25 | 1.49 | 2.67 | |
| Regeneron Pharmaceuticals Inc. | 4.47 | 3.82 | 2.56 | 3.59 | 3.31 | |
| Current Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | 1.70 | 1.82 | 2.14 | 1.92 | 2.19 | |
| Current Ratio, Industry | ||||||
| Health Care | 1.52 | 1.64 | 1.83 | 1.73 | 1.98 | |
Based on: 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19).
1 2018 Calculation
Current ratio = Current assets ÷ Current liabilities
= 20,549,600 ÷ 11,888,100 = 1.73
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Eli Lilly & Co.’s current ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |
Quick Ratio
Eli Lilly & Co., quick ratio calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Cash and cash equivalents | 7,998,200 | 6,536,200 | 4,582,100 | 3,666,400 | 3,871,600 | |
| Short-term investments | 88,200 | 1,497,900 | 1,456,500 | 785,400 | 955,400 | |
| Accounts receivable, net of allowances | 5,246,500 | 4,546,300 | 4,029,400 | 3,513,000 | 3,234,600 | |
| Other receivables | 958,400 | 715,900 | 736,900 | 558,600 | 566,700 | |
| Total quick assets | 14,291,300 | 13,296,300 | 10,804,900 | 8,523,400 | 8,628,300 | |
| Current liabilities | 11,888,100 | 14,535,900 | 10,986,600 | 8,229,600 | 11,207,500 | |
| Liquidity Ratio | ||||||
| Quick ratio1 | 1.20 | 0.91 | 0.98 | 1.04 | 0.77 | |
| Benchmarks | ||||||
| Quick Ratio, Competitors2 | ||||||
| Abbott Laboratories | 1.03 | 1.67 | 3.31 | 1.04 | 0.76 | |
| AbbVie Inc. | 0.78 | 0.89 | 1.14 | 1.21 | 1.06 | |
| Allergan PLC | 0.83 | 0.95 | 2.00 | 0.42 | 0.52 | |
| Amgen Inc. | 2.44 | 4.98 | 3.68 | 3.97 | 4.22 | |
| Biogen Inc. | 1.83 | 1.78 | 1.94 | 1.93 | 1.54 | |
| Bristol-Myers Squibb Co. | 1.37 | 1.30 | 1.27 | 1.05 | 1.26 | |
| Celgene Corp. | 2.00 | 4.67 | 3.24 | 4.05 | 4.13 | |
| Gilead Sciences Inc. | 3.15 | 2.52 | 1.78 | 2.07 | 2.56 | |
| Johnson & Johnson | 1.08 | 1.04 | 2.04 | 1.77 | 1.76 | |
| Merck & Co. Inc. | 0.72 | 0.83 | 1.24 | 1.04 | 1.19 | |
| Pfizer Inc. | 0.84 | 0.93 | 0.84 | 1.07 | 2.07 | |
| Regeneron Pharmaceuticals Inc. | 3.50 | 2.98 | 2.13 | 3.10 | 2.93 | |
| Quick Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | 1.27 | 1.42 | 1.69 | 1.48 | 1.63 | |
| Quick Ratio, Industry | ||||||
| Health Care | 1.13 | 1.29 | 1.44 | 1.33 | 1.48 | |
Based on: 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19).
1 2018 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 14,291,300 ÷ 11,888,100 = 1.20
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Eli Lilly & Co.’s quick ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |
Cash Ratio
Eli Lilly & Co., cash ratio calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Cash and cash equivalents | 7,998,200 | 6,536,200 | 4,582,100 | 3,666,400 | 3,871,600 | |
| Short-term investments | 88,200 | 1,497,900 | 1,456,500 | 785,400 | 955,400 | |
| Total cash assets | 8,086,400 | 8,034,100 | 6,038,600 | 4,451,800 | 4,827,000 | |
| Current liabilities | 11,888,100 | 14,535,900 | 10,986,600 | 8,229,600 | 11,207,500 | |
| Liquidity Ratio | ||||||
| Cash ratio1 | 0.68 | 0.55 | 0.55 | 0.54 | 0.43 | |
| Benchmarks | ||||||
| Cash Ratio, Competitors2 | ||||||
| Abbott Laboratories | 0.45 | 1.08 | 2.82 | 0.67 | 0.42 | |
| AbbVie Inc. | 0.47 | 0.59 | 0.66 | 0.77 | 0.73 | |
| Allergan PLC | 0.33 | 0.65 | 1.68 | 0.13 | 0.05 | |
| Amgen Inc. | 2.17 | 4.62 | 3.40 | 3.62 | 3.86 | |
| Biogen Inc. | 1.07 | 1.10 | 1.43 | 1.33 | 0.83 | |
| Bristol-Myers Squibb Co. | 0.83 | 0.71 | 0.72 | 0.53 | 0.88 | |
| Celgene Corp. | 1.49 | 4.03 | 2.69 | 3.33 | 3.57 | |
| Gilead Sciences Inc. | 2.84 | 2.19 | 1.29 | 1.48 | 1.76 | |
| Johnson & Johnson | 0.63 | 0.60 | 1.59 | 1.38 | 1.32 | |
| Merck & Co. Inc. | 0.40 | 0.46 | 0.83 | 0.70 | 0.84 | |
| Pfizer Inc. | 0.59 | 0.66 | 0.57 | 0.79 | 1.67 | |
| Regeneron Pharmaceuticals Inc. | 1.95 | 1.24 | 0.84 | 1.29 | 1.38 | |
| Cash Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | 0.87 | 1.03 | 1.29 | 1.08 | 1.21 | |
| Cash Ratio, Industry | ||||||
| Health Care | 0.73 | 0.90 | 1.03 | 0.94 | 1.07 | |
Based on: 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19).
1 2018 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 8,086,400 ÷ 11,888,100 = 0.68
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Eli Lilly & Co.’s cash ratio improved from 2016 to 2017 and from 2017 to 2018. |